Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Zura Bio Limited (NASDAQ:ZURA) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $10.75.

Several analysts have recently weighed in on the company. Chardan Capital reissued a “buy” rating and issued a $10.00 target price on shares of Zura Bio in a report on Friday, November 14th. Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a research report on Sunday, November 23rd. Wall Street Zen downgraded Zura Bio from a “hold” rating to a “sell” rating in a report on Sunday, November 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Tuesday, October 14th.

Zura Bio Price Performance

NASDAQ ZURA opened at $5.12 on Friday. The firm’s fifty day moving average price is $4.20 and its 200 day moving average price is $2.94. The company has a market capitalization of $332.90 million, a price-to-earnings ratio of -7.88 and a beta of 0.20. Zura Bio has a 12 month low of $0.97 and a 12 month high of $5.75.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). As a group, sell-side analysts forecast that Zura Bio will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Savant Capital LLC boosted its stake in shares of Zura Bio by 190.4% during the second quarter. Savant Capital LLC now owns 32,409 shares of the company’s stock worth $34,000 after buying an additional 21,249 shares during the period. Scientech Research LLC acquired a new position in Zura Bio in the 3rd quarter valued at about $45,000. AQR Capital Management LLC purchased a new stake in Zura Bio during the 1st quarter valued at approximately $72,000. Nuveen LLC acquired a new stake in Zura Bio during the 1st quarter worth approximately $76,000. Finally, Forefront Wealth Partners LLC acquired a new stake in Zura Bio during the 3rd quarter worth approximately $93,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.